In September 2019, New B Innovation Biopharmaceutical (Ireland) Limited changed name to New Beta Innovation Biopharmaceutical (Ireland) Limited.
On 21 March 2016, orphan designation (EU/3/16/1628) was granted by the European Commission to New B Innovation (UK) Limited, United Kingdom, for diaspirin cross-linked haemoglobin (also called YQ23) for the treatment of oesophageal cancer.
The sponsorship was transferred to New B Innovation Biopharmaceutical (Ireland) Limited, Ireland, in April 2019.
Diaspirin cross-linked haemoglobin
|Disease / condition||
Treatment of oesophageal cancer
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;